Cavallaro Palmira Alessia, De Santo Marzia, Belsito Emilia Lucia, Longobucco Camilla, Curcio Manuela, Morelli Catia, Pasqua Luigi, Leggio Antonella
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Rende, Italy.
Department of Environmental Engineering, University of Calabria, Via P. Bucci, 87036 Rende, Italy.
Nanomaterials (Basel). 2023 Sep 1;13(17):2476. doi: 10.3390/nano13172476.
Breast cancer represents the most common cancer type and one of the major leading causes of death in the female worldwide population. Overexpression of HER2, a transmembrane glycoprotein related to the epidermal growth factor receptor, results in a biologically and clinically aggressive breast cancer subtype. It is also the primary driver for tumor detection and progression and, in addition to being an important prognostic factor in women diagnosed with breast cancer, HER2 is a widely known therapeutic target for drug development. The aim of this review is to provide an updated overview of the main approaches for the diagnosis and treatment of HER2-positive breast cancer proposed in the literature over the past decade. We focused on the different targeting strategies involving antibodies and peptides that have been explored with their relative outcomes and current limitations that need to be improved. The review also encompasses a discussion on targeted peptides acting as probes for molecular imaging. By using different types of HER2-targeting strategies, nanotechnology promises to overcome some of the current clinical challenges by developing novel HER2-guided nanosystems suitable as powerful tools in breast cancer imaging, targeting, and therapy.
乳腺癌是全球女性中最常见的癌症类型，也是主要的死亡原因之一。HER2是一种与表皮生长因子受体相关的跨膜糖蛋白，其过表达会导致一种具有生物学和临床侵袭性的乳腺癌亚型。它也是肿瘤检测和进展的主要驱动因素，除了是诊断为乳腺癌的女性的重要预后因素外，HER2还是药物开发中广为人知的治疗靶点。本综述的目的是提供过去十年文献中提出的HER2阳性乳腺癌诊断和治疗主要方法的最新概述。我们重点关注了涉及抗体和肽的不同靶向策略，探讨了它们的相对结果以及需要改进的当前局限性。该综述还包括对作为分子成像探针的靶向肽的讨论。通过使用不同类型的HER2靶向策略，纳米技术有望通过开发新型HER2导向纳米系统来克服当前的一些临床挑战，这些纳米系统适合作为乳腺癌成像、靶向和治疗的强大工具。
